JPMorgan Chase & Co. Initiates Coverage on CeriBell (NASDAQ:CBLL)

Equities research analysts at JPMorgan Chase & Co. began coverage on shares of CeriBell (NASDAQ:CBLL) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $32.00 price target on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 15.19% from the company’s previous close.

A number of other equities research analysts have also recently commented on CBLL. William Blair began coverage on shares of CeriBell in a report on Tuesday. They issued an “outperform” rating on the stock. TD Cowen began coverage on shares of CeriBell in a report on Tuesday. They issued a “buy” rating and a $31.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.00.

CeriBell Price Performance

NASDAQ:CBLL opened at $27.78 on Tuesday. CeriBell has a 12 month low of $23.00 and a 12 month high of $28.94.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.